Several other groups outside Asia have reported their experience of panel testing in patients who initially test negative for BRCA1/2, identifying pathogenic variants in other moderate penetrance breast cancer genes in 7 – 10% of their cohorts, although most of these cohorts included only a minority of patients with multiple primary cancers [9–12]. This evidence concerns the gene BRCA1 and breast cancer.